November 2014

The Economic Impact of “Canada’s” Chronic Conditions: Living with Crohn’s and Colitis

11:45am-1:30pm | One King West Hotel - 1 King West, Toronto

Canadians have more reasons to be concerned about Crohn’s and colitis than anyone else in the world. One in every 150 Canadians suffers from Crohn’s and colitis, the two most common forms of Inflammatory Bowel Disease (IBD), a rate that ranks among the highest worldwide. Families new to Canada, predominantly those of South Eastern Asian descent, are developing Crohn’s and colitis for the first time – often within the first generation. These diseases are escalating in children at an alarming rate, especially those under 10 years old. In Ontario, over the past 15 years, the number of children with IBD has increased by more than 40%. With an expected 10,200 new diagnoses every year, in addition to the nearly quarter of a million Canadian living with Crohn’s and colitis, these diseases are becoming common in Canada. IBD is more than twice as common as Multiple Sclerosis or Parkinson’s disease and is about as common as Type 1 Diabetes or Epilepsy.
In the spirit of November Awareness month, Lindee David, CEO of Crohn’s and Colitis Canada, with special presenter, Dr. Eric Benchimol, a pediatric gastroenterologist, will illustrate the economic impact of these chronic conditions in Canada and speak to why Canada is becoming a world leader in IBD research and care, having funded more than $88 million to date. The talk will spotlight a business solution to improving quality of life for people affected by Crohn’s and colitis.

Lindee David, Chief Executive Officer for Crohn’s and Colitis Canada with a special presentation by Dr. Eric Benchimol, Pediatric Gastroenterologist at the Children’s Hospital of Eastern Ontario (CHEO) and an Assistant Professor of Pediatrics and Epidemiology at the University of Ottawa.

Member Pricing:
Individual seat: $89 +HST
Table (seats 10): $801 +HST
Guest Pricing:
Individual: $110 +HST
Table (seats 10): $990 +HST

The Economic Impact of “Canada’s” Chronic Conditions: Living with Crohn’s and Colitis

Dr. Eric Benchimol

Assistant Professor of Pediatrics and Epidemiology
University of Ottawa

Dr. Eric Benchimol

Eric Benchimol is an Assistant Professor in the Department of Pediatrics and the Department of Epidemiology and Community Medicine at the University of Ottawa. He is also a pediatric gastroenterologist in the Division of Gastroenterology, Hepatology and Nutrition at the Children’s Hospital of Eastern Ontario (CHEO), a scientist at the CHEO Research Institute, and an adjunct scientist at The Institute for Clinical Evaluative Sciences (ICES). He received a Bachelor’s of Science degree in biology and genetics from York University, and a medical degree from the University of Western Ontario. He also completed a residency in pediatrics at CHEO, fellowships in pediatric gastroenterology and inflammatory bowel diseases at The Hospital for Sick Children, and received a PhD in clinical epidemiology at the University of Toronto.

Dr. Benchimol conducts epidemiology, outcomes, and health services research in patients with inflammatory bowel disease (IBD) using health administrative data, as well as in children with other chronic diseases. His work created The Ontario Crohn’s and Colitis Cohort, the world’s largest ongoing surveillance cohort of IBD patients. Dr. Benchimol also chairs the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC), funded in part by Crohn’s and Colitis Canada, which conducts national research on IBD and other chronic illnesses. He was recently awarded the prestigious New Investigator Award from Crohn’s and Colitis Canada, the Canadian Institutes of Health Research, and the Canadian Association of Gastroenterology.

Lindee David

Chief Executive Officer
Crohn’s and Colitis Canada

Lindee David

Lindee David assumed leadership of Crohn’s and Colitis Canada on June 2, 2014 as its new Chief Executive Officer. She is a strategic, innovative healthcare executive with blended leadership experience in both the corporate and non-profit sectors. As CEO of ALS Canada she has led recent transformational change resulting in a financially sustainable organization.
Previously, Lindee held senior level positions with Janssen Canada, a division of Johnson & Johnson, including leadership of business units. During a decade with Janssen, she led business teams, the development of new selling models, market access programs and multi-million dollar contract negotiations with health care buying groups.
Her passion for social change was exhibited during the blood scandal as the Executive Director of the Canadian Hemophilia Society. For nine years, she advocated on behalf of recipients of blood and blood products resulting in the largest-ever government settlement for those infected with contaminated blood and the establishment of an independent agency to manage Canada’s blood system.
Lindee and her family, Michel, Christopher and Carolyn are outdoor enthusiasts enjoying sailing, hiking and biking in the summer months and skiing in winter.

Our Sponsors

Telus Interac Green Shield Canada